Quick Takeaways
- BlackRock, Inc. filed SCHEDULE 13G/A for ZENTALIS PHARMACEUTICALS INC Common Stock (ZNTL).
- Disclosed ownership: 2.2%.
- Date of event: 30 Jun 2025.
BlackRock, Inc. - 30 Jun 2025 SCHEDULE 13G/A Report for ZENTALIS PHARMACEUTICALS INC Common Stock (ZNTL)
- Filing Manager
- BlackRock, Inc.
- Reporting Manager
- BlackRock, Inc.
- Symbol
- ZNTL
- Shares outstanding
- 73,332,864 shares
- Disclosed Ownership
- 1,613,323 shares
- Ownership
- 2.2%
- Form type
- SCHEDULE 13G/A
- Filing time
- 16 Jul 2025, 19:02:18 UTC
- Date of event
- 30 Jun 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"BlackRock, Inc. disclosed 2.2% ownership in ZENTALIS PHARMACEUTICALS INC Common Stock (ZNTL) on 30 Jun 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 16 Jul 2025, 19:02.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 2.2% | 1,613,323 | 1,599,809 | 0 | Spencer Fleming | Managing Director |